For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

According to EDX, the test studies the most comprehensive range of clinically validated prostate-related biomarkers currently ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.

This is a retrospective, observational, multicenter, longitudinal follow-up study to describe the treatment patterns received by the Spanish patients who received darolutamide in the ARAMIS study, ...

The Sunday Mail Dr Aspect Maunganidze Tanyaradzwa Rusike TWO new cancer treatment centres are set to be established at the Gweru Provincial Hospital and the Victoria Chitepo Provincial Hospital in ...

The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.